Comparative Pharmacology
Head-to-head clinical analysis: ELIFEMME versus ORTHO NOVUM 7 7 7 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIFEMME versus ORTHO NOVUM 7 7 7 21.
ELIFEMME vs ORTHO-NOVUM 7/7/7-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elifemme is a small-molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD4. It disrupts the interaction between BET proteins and acetylated histones, thereby inhibiting oncogene transcription including MYC and BCL2.
Combined hormonal contraceptive; primarily suppresses ovulation via inhibition of gonadotropin release (LH and FSH) from the pituitary. Also induces changes in cervical mucus and endometrium.
Subcutaneous injection: 0.5 mL (15 mg) once weekly.
One tablet orally once daily for 21 days, followed by 7 days of no tablets. Each tablet contains norethindrone 0.5 mg/0.75 mg/1 mg and ethinyl estradiol 35 mcg, with biphasic or triphasic dosing per cycle.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours, allowing once-daily dosing for treatment of relapsed/refractory multiple myeloma.
Ethinyl estradiol: 13-27 hours; norethindrone: 8-14 hours; with multiple dosing, steady state after 5-7 days.
Primarily unchanged in feces (approx. 60-70%) via biliary excretion, with renal excretion accounting for <10% of the dose.
Renal: <10% unchanged; biliary/fecal: ~50% as metabolites; extensive enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive